November 14, 2010 / 6:08 PM / 7 years ago

Mela shares could double or fall by half-Barron's

NEW YORK, Nov 14 (Reuters) - Mela Sciences Inc MELA.O shares could double if a regulatory panel this week decides to recommend approval of the company’s melanoma screening device, Barron’s wrote in its Nov. 15 issue.

A panel of the U.S. Food Drug Administration is set on Thursday to vote on whether to recommend approval of the MelaFind device. But a “no” vote could cut the share price in half, the financial weekly wrote.

Mela shares hit a yearly low of $5.23 on the Nasdaq Stock Market on Friday. They have tumbled more than half since hitting a 52-week high in January. (Reporting by Phil Wahba, editing by Martin Golan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below